Vanutide cridificar

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameVanutide cridificar
Drug Alias Namevanutida cridificar克卡伐肽可利卡-伐努肽Aβ immunotherapeutic conjugatePeptide-CRM Conjugate +[12] 
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyFrance +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer IncElan Pharma International LtdJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJanssen Alzheimer Immunotherapy Research & Development LlcPfizer Inc
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A